This project has received funding from the Eurostars-3 joint program with co-financing from CDTI and the Horizon Europe Research and Innovation Framework Programme of the European Union. The RaDiPaEm project consortium is led by the Spanish company PULSO EDICIONES, S.L., and includes the participation of the Swiss company Definition12 Ltd., the German company GENIE ENTERPRISE Inc., and the Spanish company IOMED Medical Solutions SLThe RaDiPaEm solution will use of Natural Language Processing and Deep Learning technology to create algorithms that allow health professionals to perform early detection of rare diseases, based on the medical history of patients who already suffer from them. In order to develop these algorithms, we are seeking to obtain real clinical information from a large number of patients throughout Europe diagnosed with rare diseases.The RaDiPaEm solution will empower patients suffering from these diseases through an APP that will allow them to centralize and digitize all their medical records, easily accessing to this information through a dynamic chatbot.Patients using RaDiPaEm will provide data for their own purpose: to receive help and decision support as a result of the aggregated data model from the above analysis cross-referenced with their own data.These data, conveniently anonymized and aggregated, will be reported within the framework of a clinical study. One of the targets of RaDiPaEm is to update the Clinical Guidelines based on real data based on the reports that will be produced.RaDiPaEm will represent a new paradigm in understanding the real difficulties to diagnose, due to the lack of real data, as soon as possible with the lowest possible cost to a patient with a rare disease. The project is an opportunity to empower patients and health professionals to self-manage their disease, but also, to contribute to the scientific community.

‍